[
    {
        "guideline_name": "ACC/AHA Chest Pain Guidelines 2021",
        "section": "Initial Evaluation",
        "content": "For patients presenting with acute chest pain, obtain a 12-lead ECG within 10 minutes of arrival. Patients with ST-elevation require immediate reperfusion therapy. For non-ST elevation, risk stratify using validated scores (HEART, TIMI). High-sensitivity troponin should be obtained at presentation and repeated at 1-3 hours.",
        "source": "Gulati M, et al. 2021 AHA/ACC Guideline for Chest Pain. Circulation. 2021;144:e364-e454",
        "evidence_level": "Level A",
        "condition": "Chest Pain"
    },
    {
        "guideline_name": "ACC/AHA Chest Pain Guidelines 2021",
        "section": "Risk Stratification",
        "content": "The HEART score (History, ECG, Age, Risk factors, Troponin) is recommended for risk stratification of acute chest pain. Score 0-3: low risk (0.9-1.7% 6-week MACE), consider discharge. Score 4-6: intermediate risk, observation/stress testing. Score 7-10: high risk, admission and cardiology consultation.",
        "source": "Gulati M, et al. 2021 AHA/ACC Guideline for Chest Pain. Circulation. 2021;144:e364-e454",
        "evidence_level": "Level A",
        "condition": "Chest Pain"
    },
    {
        "guideline_name": "ACC/AHA Chest Pain Guidelines 2021",
        "section": "Imaging Recommendations",
        "content": "For intermediate-risk patients with acute chest pain, coronary CT angiography (CCTA) is recommended as first-line imaging if available and patient is suitable. Alternative stress testing (stress echo, nuclear imaging) is appropriate when CCTA is not available or contraindicated. Chest X-ray should be obtained to evaluate for alternative diagnoses.",
        "source": "Gulati M, et al. 2021 AHA/ACC Guideline for Chest Pain. Circulation. 2021;144:e364-e454",
        "evidence_level": "Level A",
        "condition": "Chest Pain"
    },
    {
        "guideline_name": "ACC/AHA Chest Pain Guidelines 2021",
        "section": "Non-Cardiac Causes",
        "content": "Consider non-cardiac causes of chest pain including pulmonary embolism, pneumothorax, aortic dissection, esophageal rupture, and tension pneumothorax. D-dimer and CT pulmonary angiography for PE evaluation. Chest X-ray and CT for pneumothorax. CT angiography for suspected aortic dissection. Maintain high clinical suspicion in appropriate clinical context.",
        "source": "Gulati M, et al. 2021 AHA/ACC Guideline for Chest Pain. Circulation. 2021;144:e364-e454",
        "evidence_level": "Level B",
        "condition": "Chest Pain"
    },
    {
        "guideline_name": "IDSA/ATS Community-Acquired Pneumonia Guidelines 2019",
        "section": "Diagnosis",
        "content": "Diagnosis of CAP requires demonstration of an infiltrate on chest imaging (radiograph or CT) in a patient with compatible clinical features (cough, fever, sputum production, dyspnea, pleuritic chest pain). Procalcitonin can help guide antibiotic decisions. Blood cultures recommended for severe CAP. Sputum Gram stain and culture if quality specimen obtainable.",
        "source": "Metlay JP, et al. ATS/IDSA CAP Guidelines 2019. Am J Respir Crit Care Med. 2019;200:e45-e67",
        "evidence_level": "Level A",
        "condition": "Pneumonia"
    },
    {
        "guideline_name": "IDSA/ATS Community-Acquired Pneumonia Guidelines 2019",
        "section": "Severity Assessment",
        "content": "Use CURB-65 or PSI/PORT score to assess pneumonia severity and guide site of care. CURB-65: Confusion, Urea >7mmol/L, Respiratory rate >=30, BP <90/60, Age >=65. Score 0-1: outpatient. Score 2: consider admission. Score 3-5: severe pneumonia, consider ICU. PSI Class I-III: outpatient. Class IV-V: inpatient.",
        "source": "Metlay JP, et al. ATS/IDSA CAP Guidelines 2019. Am J Respir Crit Care Med. 2019;200:e45-e67",
        "evidence_level": "Level A",
        "condition": "Pneumonia"
    },
    {
        "guideline_name": "IDSA/ATS Community-Acquired Pneumonia Guidelines 2019",
        "section": "Treatment - Outpatient",
        "content": "For outpatient CAP without comorbidities: Amoxicillin 1g TID or Doxycycline 100mg BID or Azithromycin 500mg day 1 then 250mg daily. With comorbidities (COPD, diabetes, CKD, heart failure): Amoxicillin-clavulanate PLUS azithromycin OR respiratory fluoroquinolone monotherapy. Duration 5 days typically sufficient.",
        "source": "Metlay JP, et al. ATS/IDSA CAP Guidelines 2019. Am J Respir Crit Care Med. 2019;200:e45-e67",
        "evidence_level": "Level A",
        "condition": "Pneumonia"
    },
    {
        "guideline_name": "IDSA/ATS Community-Acquired Pneumonia Guidelines 2019",
        "section": "Treatment - Inpatient",
        "content": "For non-severe inpatient CAP: Beta-lactam (ceftriaxone, ampicillin-sulbactam, or cefotaxime) PLUS macrolide OR respiratory fluoroquinolone monotherapy. For severe CAP: Beta-lactam PLUS macrolide OR beta-lactam PLUS fluoroquinolone. Consider anti-pseudomonal coverage if risk factors present.",
        "source": "Metlay JP, et al. ATS/IDSA CAP Guidelines 2019. Am J Respir Crit Care Med. 2019;200:e45-e67",
        "evidence_level": "Level A",
        "condition": "Pneumonia"
    },
    {
        "guideline_name": "ACC/AHA/HFSA Heart Failure Guidelines 2022",
        "section": "Diagnosis",
        "content": "Heart failure diagnosis requires symptoms (dyspnea, orthopnea, fatigue, edema) with objective evidence of cardiac dysfunction. BNP >=100 pg/mL or NT-proBNP >=300 pg/mL supports diagnosis. Echocardiography is essential to assess EF and classify as HFrEF (<=40%), HFmrEF (41-49%), or HFpEF (>=50%). Chest X-ray may show cardiomegaly, pulmonary congestion.",
        "source": "Heidenreich PA, et al. 2022 ACC/AHA/HFSA Heart Failure Guideline. Circulation. 2022;145:e895-e1032",
        "evidence_level": "Level A",
        "condition": "Heart Failure"
    },
    {
        "guideline_name": "ACC/AHA/HFSA Heart Failure Guidelines 2022",
        "section": "HFrEF Treatment",
        "content": "For HFrEF (EF <=40%), guideline-directed medical therapy includes: ACE inhibitor/ARB/ARNI, beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), mineralocorticoid receptor antagonist (spironolactone or eplerenone), and SGLT2 inhibitor (dapagliflozin or empagliflozin). These four pillars reduce mortality and hospitalization.",
        "source": "Heidenreich PA, et al. 2022 ACC/AHA/HFSA Heart Failure Guideline. Circulation. 2022;145:e895-e1032",
        "evidence_level": "Level A",
        "condition": "Heart Failure"
    },
    {
        "guideline_name": "ACC/AHA/HFSA Heart Failure Guidelines 2022",
        "section": "Acute Decompensation",
        "content": "For acute decompensated heart failure: IV diuretics (furosemide) for congestion relief. Assess volume status and perfusion. Warm and wet: diuretics +/- vasodilators. Cold and wet: consider inotropes with diuretics. Cold and dry: cautious fluids. Monitor daily weights, I/O, renal function. Early follow-up within 7-14 days post-discharge.",
        "source": "Heidenreich PA, et al. 2022 ACC/AHA/HFSA Heart Failure Guideline. Circulation. 2022;145:e895-e1032",
        "evidence_level": "Level A",
        "condition": "Heart Failure"
    },
    {
        "guideline_name": "ACC/AHA/HFSA Heart Failure Guidelines 2022",
        "section": "Imaging in Heart Failure",
        "content": "Chest X-ray findings in heart failure include: cardiomegaly (cardiothoracic ratio >0.5), cephalization of pulmonary vessels, interstitial edema (Kerley B lines), alveolar edema (bat-wing pattern), pleural effusions. Repeat imaging for acute changes. Echocardiography for EF assessment and structural evaluation.",
        "source": "Heidenreich PA, et al. 2022 ACC/AHA/HFSA Heart Failure Guideline. Circulation. 2022;145:e895-e1032",
        "evidence_level": "Level B",
        "condition": "Heart Failure"
    },
    {
        "guideline_name": "GOLD COPD Guidelines 2024",
        "section": "Diagnosis",
        "content": "COPD diagnosis requires spirometry showing post-bronchodilator FEV1/FVC <0.7 in a patient with respiratory symptoms and exposure history. Severity by FEV1: GOLD 1 (>=80%), GOLD 2 (50-79%), GOLD 3 (30-49%), GOLD 4 (<30%). ABE assessment tool categorizes by exacerbation history and symptoms (mMRC/CAT).",
        "source": "Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 Report",
        "evidence_level": "Level A",
        "condition": "COPD"
    },
    {
        "guideline_name": "GOLD COPD Guidelines 2024",
        "section": "Stable COPD Treatment",
        "content": "Initial pharmacotherapy based on ABE group. Group A: bronchodilator (SABA, SAMA, or LABA, LAMA). Group B: LABA + LAMA combination. Group E (frequent exacerbators): LABA + LAMA, consider adding ICS if blood eosinophils >=300. Triple therapy (LABA + LAMA + ICS) for persistent exacerbations despite dual therapy.",
        "source": "Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 Report",
        "evidence_level": "Level A",
        "condition": "COPD"
    },
    {
        "guideline_name": "GOLD COPD Guidelines 2024",
        "section": "Exacerbation Management",
        "content": "COPD exacerbation: acute worsening of respiratory symptoms requiring additional therapy. Treatment: Short-acting bronchodilators (SABA +/- SAMA), systemic corticosteroids (prednisone 40mg x 5 days), antibiotics if increased sputum purulence (amoxicillin-clavulanate, azithromycin, or respiratory fluoroquinolone). Supplemental O2 to target SpO2 88-92%.",
        "source": "Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 Report",
        "evidence_level": "Level A",
        "condition": "COPD"
    },
    {
        "guideline_name": "GOLD COPD Guidelines 2024",
        "section": "Imaging in COPD",
        "content": "Chest X-ray in COPD may show hyperinflation, flattened diaphragms, increased AP diameter, and bullae. CT chest provides detailed assessment of emphysema pattern and severity. Chest imaging helps exclude alternative diagnoses and identify complications (pneumonia, pneumothorax, lung cancer). Annual LDCT recommended for lung cancer screening in appropriate patients.",
        "source": "Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 Report",
        "evidence_level": "Level B",
        "condition": "COPD"
    },
    {
        "guideline_name": "Fleischner Society Pulmonary Nodule Guidelines 2017",
        "section": "Solid Nodule Management",
        "content": "For incidental solid pulmonary nodules in low-risk patients: <6mm no follow-up needed. 6-8mm: CT at 6-12 months, consider CT at 18-24 months. >8mm: CT at 3 months, PET/CT, or tissue sampling. High-risk patients (smoking history, upper lobe location): more aggressive surveillance. Multiple nodules: follow the dominant nodule.",
        "source": "MacMahon H, et al. Fleischner Society Guidelines 2017. Radiology. 2017;284:228-243",
        "evidence_level": "Level B",
        "condition": "Lung Nodule"
    },
    {
        "guideline_name": "Fleischner Society Pulmonary Nodule Guidelines 2017",
        "section": "Ground-Glass Nodule Management",
        "content": "For ground-glass nodules (GGN): <6mm no follow-up if solitary in low-risk patient. >=6mm: CT at 6-12 months to confirm persistence, then CT every 2 years until 5 years. Part-solid nodules: follow the solid component. Solid component >=6mm or growing: consider biopsy or resection. PET often negative for pure GGN.",
        "source": "MacMahon H, et al. Fleischner Society Guidelines 2017. Radiology. 2017;284:228-243",
        "evidence_level": "Level B",
        "condition": "Lung Nodule"
    },
    {
        "guideline_name": "USPSTF Lung Cancer Screening 2021",
        "section": "Screening Recommendations",
        "content": "Annual low-dose CT (LDCT) lung cancer screening recommended for adults 50-80 years with 20+ pack-year smoking history who currently smoke or quit within past 15 years. Screening should stop when patient has not smoked for 15 years or develops a health problem limiting life expectancy or ability to have curative lung surgery.",
        "source": "US Preventive Services Task Force. JAMA. 2021;325:962-970",
        "evidence_level": "Level A",
        "condition": "Lung Cancer Screening"
    },
    {
        "guideline_name": "NCCN Lung Cancer Guidelines 2024",
        "section": "Initial Workup",
        "content": "For suspected lung cancer: Complete staging workup including CT chest/abdomen with contrast, PET/CT, brain MRI (for stage IB and higher). Tissue diagnosis via least invasive method (bronchoscopy, CT-guided biopsy, EBUS, or surgical). Molecular testing for EGFR, ALK, ROS1, BRAF, KRAS G12C, NTRK, MET, RET, and PD-L1 for advanced NSCLC.",
        "source": "NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 1.2024",
        "evidence_level": "Level A",
        "condition": "Lung Cancer"
    },
    {
        "guideline_name": "NCCN Lung Cancer Guidelines 2024",
        "section": "Suspicious Mass Workup",
        "content": "For lung mass suspicious for malignancy: CT chest with contrast for characterization. PET/CT for metabolic activity assessment (SUV >2.5 concerning). Tissue diagnosis required before treatment. For central lesions: bronchoscopy with EBUS. For peripheral lesions: CT-guided biopsy or navigational bronchoscopy. Consider surgical resection for highly suspicious lesions in operable patients.",
        "source": "NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 1.2024",
        "evidence_level": "Level A",
        "condition": "Lung Cancer"
    },
    {
        "guideline_name": "ATS/ERS Interstitial Lung Disease Guidelines 2018",
        "section": "IPF Diagnosis",
        "content": "Idiopathic pulmonary fibrosis (IPF) diagnosis requires exclusion of known causes and either UIP pattern on HRCT (basal-predominant honeycombing, traction bronchiectasis, reticulation) or histopathologic UIP pattern. Multidisciplinary discussion recommended. BAL and surgical lung biopsy may be needed if imaging is indeterminate.",
        "source": "Raghu G, et al. ATS/ERS/JRS/ALAT IPF Guidelines. Am J Respir Crit Care Med. 2018;198:e44-e68",
        "evidence_level": "Level A",
        "condition": "Interstitial Lung Disease"
    },
    {
        "guideline_name": "ATS/ERS Interstitial Lung Disease Guidelines 2018",
        "section": "ILD Workup",
        "content": "For suspected ILD: HRCT chest is essential for pattern recognition. Pulmonary function tests (FVC, DLCO) for severity and monitoring. Autoimmune serologies (ANA, RF, anti-CCP, myositis panel) to exclude CTD-ILD. Consider bronchoscopy with BAL and possible surgical lung biopsy for diagnosis. Six-minute walk test for functional assessment.",
        "source": "Raghu G, et al. ATS/ERS/JRS/ALAT IPF Guidelines. Am J Respir Crit Care Med. 2018;198:e44-e68",
        "evidence_level": "Level B",
        "condition": "Interstitial Lung Disease"
    },
    {
        "guideline_name": "PESI Pulmonary Embolism Severity Index",
        "section": "Risk Stratification",
        "content": "PESI score for PE risk stratification: Age (years), Male (+10), Cancer (+30), Heart failure (+10), Chronic lung disease (+10), HR >=110 (+20), SBP <100 (+30), RR >=30 (+20), Temp <36C (+20), Altered mental status (+60), SpO2 <90% (+20). Class I-II (<=85): low risk, consider outpatient. Class III-V (>85): higher risk, inpatient management.",
        "source": "Aujesky D, et al. Am J Respir Crit Care Med. 2005;172:1041-1046",
        "evidence_level": "Level A",
        "condition": "Pulmonary Embolism"
    },
    {
        "guideline_name": "ACCP/ATS Pulmonary Embolism Guidelines 2016",
        "section": "Diagnosis",
        "content": "For suspected PE: Assess pre-test probability using Wells or Geneva score. Low probability + negative D-dimer: PE excluded. Intermediate/high probability or positive D-dimer: CT pulmonary angiography (CTPA). V/Q scan alternative if contrast contraindicated. Lower extremity ultrasound if DVT symptoms. Start anticoagulation if high clinical suspicion while awaiting imaging.",
        "source": "Kearon C, et al. CHEST Guideline on VTE. Chest. 2016;149:315-352",
        "evidence_level": "Level A",
        "condition": "Pulmonary Embolism"
    },
    {
        "guideline_name": "ACCP/ATS Pulmonary Embolism Guidelines 2016",
        "section": "Treatment",
        "content": "For acute PE without hemodynamic instability: Anticoagulation with DOAC (rivaroxaban, apixaban, edoxaban, dabigatran) preferred over warfarin. LMWH bridge if using warfarin or dabigatran/edoxaban. Duration: 3 months minimum, extended if unprovoked and low bleeding risk. For massive PE with hypotension: consider systemic thrombolysis, catheter-directed therapy, or embolectomy.",
        "source": "Kearon C, et al. CHEST Guideline on VTE. Chest. 2016;149:315-352",
        "evidence_level": "Level A",
        "condition": "Pulmonary Embolism"
    },
    {
        "guideline_name": "BTS Pleural Effusion Guidelines 2023",
        "section": "Diagnostic Approach",
        "content": "For new pleural effusion: Chest X-ray confirms presence (blunting of costophrenic angle with >200mL fluid). Ultrasound guides thoracentesis and characterizes effusion. Diagnostic thoracentesis if >10mm depth and cause unclear. Send for protein, LDH, pH, glucose, cell count, cytology, and culture. Light's criteria differentiates exudate vs transudate.",
        "source": "Roberts ME, et al. BTS Pleural Disease Guideline 2023. Thorax. 2023;78:s1-s42",
        "evidence_level": "Level A",
        "condition": "Pleural Effusion"
    },
    {
        "guideline_name": "BTS Pleural Effusion Guidelines 2023",
        "section": "Management",
        "content": "Management based on etiology: Transudative (CHF, cirrhosis, nephrotic): treat underlying cause, diuretics. Parapneumonic: antibiotics, drainage if complicated (pH <7.2, glucose <60, or loculated). Malignant: symptomatic drainage, consider pleurodesis or indwelling catheter for recurrent. Empyema: chest tube drainage and antibiotics, consider thoracoscopy if not resolving.",
        "source": "Roberts ME, et al. BTS Pleural Disease Guideline 2023. Thorax. 2023;78:s1-s42",
        "evidence_level": "Level A",
        "condition": "Pleural Effusion"
    },
    {
        "guideline_name": "ACEP Pneumothorax Guidelines",
        "section": "Management",
        "content": "For primary spontaneous pneumothorax: Small (<2cm at hilum) + asymptomatic: observation with O2, repeat CXR in 3-6 hours. Large or symptomatic: aspiration or chest tube. Tension pneumothorax: immediate needle decompression (2nd intercostal space, midclavicular line) followed by chest tube. Secondary pneumothorax generally requires admission and chest tube regardless of size.",
        "source": "Yarmus L, Feller-Kopman D. Management of Pneumothorax. CHEST. 2012;142:1249-1259",
        "evidence_level": "Level B",
        "condition": "Pneumothorax"
    },
    {
        "guideline_name": "ATS Tuberculosis Guidelines 2016",
        "section": "Diagnosis",
        "content": "For suspected pulmonary TB: Chest X-ray (upper lobe infiltrates, cavitation, miliary pattern). Collect 3 sputum specimens for AFB smear and culture. NAAT (GeneXpert) for rapid detection and rifampin resistance. Interferon-gamma release assay (IGRA) or TST for latent TB screening. Consider bronchoscopy with BAL if sputum-negative. Airborne isolation until TB excluded or treated.",
        "source": "Lewinsohn DM, et al. ATS/IDSA/CDC TB Guidelines. Clin Infect Dis. 2017;64:e1-e33",
        "evidence_level": "Level A",
        "condition": "Tuberculosis"
    },
    {
        "guideline_name": "ATS/IDSA Tuberculosis Guidelines 2016",
        "section": "Treatment - Active TB",
        "content": "Standard treatment for drug-susceptible pulmonary TB: Intensive phase (2 months) - isoniazid, rifampin, pyrazinamide, ethambutol (HRZE). Continuation phase (4 months) - isoniazid and rifampin (HR). Total duration 6 months. DOT recommended. Monitor LFTs, vision (ethambutol). Pyridoxine 25-50mg daily to prevent isoniazid neuropathy.",
        "source": "Nahid P, et al. ATS/CDC/IDSA Treatment of TB. Clin Infect Dis. 2016;63:e147-e195",
        "evidence_level": "Level A",
        "condition": "Tuberculosis"
    },
    {
        "guideline_name": "ATS/IDSA Tuberculosis Guidelines 2016",
        "section": "Latent TB Treatment",
        "content": "Latent TB infection (LTBI) treatment options: 3 months isoniazid + rifapentine weekly (3HP) - preferred. 4 months rifampin daily (4R). 6-9 months isoniazid daily (6H/9H). Treat LTBI in high-risk groups: HIV, recent TB contact, immunosuppression, TNF inhibitors, pre-transplant. Exclude active TB before starting LTBI treatment.",
        "source": "Nahid P, et al. ATS/CDC/IDSA Treatment of TB. Clin Infect Dis. 2016;63:e147-e195",
        "evidence_level": "Level A",
        "condition": "Tuberculosis"
    },
    {
        "guideline_name": "GINA Asthma Guidelines 2024",
        "section": "Diagnosis",
        "content": "Asthma diagnosis requires: Variable respiratory symptoms (wheeze, dyspnea, cough, chest tightness) AND variable expiratory airflow limitation (FEV1/FVC reduced, positive bronchodilator response >=12% and >=200mL, positive bronchial challenge, or PEF variability >10%). Document airflow limitation before starting ICS. FeNO >50ppb supports eosinophilic asthma.",
        "source": "Global Initiative for Asthma (GINA) 2024 Report. www.ginasthma.org",
        "evidence_level": "Level A",
        "condition": "Asthma"
    },
    {
        "guideline_name": "GINA Asthma Guidelines 2024",
        "section": "Maintenance Treatment",
        "content": "All adults with asthma should receive ICS-containing controller therapy. Track 1 (preferred): As-needed low-dose ICS-formoterol (Steps 1-2), regular ICS-formoterol (Steps 3-5). Track 2: As-needed SABA + ICS (Steps 1-2), daily ICS + as-needed SABA (Steps 3-5). Add LAMA at Step 4-5. Consider biologic therapy (anti-IgE, anti-IL5, anti-IL4R) for severe uncontrolled asthma.",
        "source": "Global Initiative for Asthma (GINA) 2024 Report. www.ginasthma.org",
        "evidence_level": "Level A",
        "condition": "Asthma"
    },
    {
        "guideline_name": "GINA Asthma Guidelines 2024",
        "section": "Acute Exacerbation",
        "content": "Acute asthma exacerbation: SABA via MDI+spacer or nebulizer. Systemic corticosteroids (prednisone 40-50mg daily x 5-7 days). Oxygen to target SpO2 93-95%. Add ipratropium for severe exacerbations. Consider IV magnesium sulfate for severe attacks not responding to initial treatment. ICU for impending respiratory failure or poor response.",
        "source": "Global Initiative for Asthma (GINA) 2024 Report. www.ginasthma.org",
        "evidence_level": "Level A",
        "condition": "Asthma"
    },
    {
        "guideline_name": "ACC/AHA Atrial Fibrillation Guidelines 2023",
        "section": "Diagnosis and Classification",
        "content": "AF diagnosis requires ECG documentation of irregularly irregular rhythm with absence of discrete P waves. Classification: paroxysmal (terminates within 7 days), persistent (>7 days), long-standing persistent (>12 months), permanent (accepted). Calculate CHA2DS2-VASc for stroke risk and HAS-BLED for bleeding risk to guide anticoagulation decisions.",
        "source": "Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS AF Guideline. Circulation. 2024;149:e1-e156",
        "evidence_level": "Level A",
        "condition": "Atrial Fibrillation"
    },
    {
        "guideline_name": "ACC/AHA Atrial Fibrillation Guidelines 2023",
        "section": "Anticoagulation",
        "content": "Anticoagulation recommended for CHA2DS2-VASc >=2 in men, >=3 in women. DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) preferred over warfarin except in moderate-severe mitral stenosis or mechanical valve. Aspirin alone NOT recommended for stroke prevention. Left atrial appendage occlusion for patients with contraindications to long-term anticoagulation.",
        "source": "Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS AF Guideline. Circulation. 2024;149:e1-e156",
        "evidence_level": "Level A",
        "condition": "Atrial Fibrillation"
    },
    {
        "guideline_name": "ACC/AHA Atrial Fibrillation Guidelines 2023",
        "section": "Rate and Rhythm Control",
        "content": "Rate control: Target resting HR <110 bpm for most; <80 if symptomatic. Beta-blockers or non-dihydropyridine CCBs (diltiazem, verapamil) first-line. Avoid CCBs in HFrEF. Rhythm control: Consider for symptomatic AF, especially if recent onset. Cardioversion after adequate anticoagulation (>=3 weeks) or TEE to exclude LAA thrombus. Catheter ablation for drug-refractory symptomatic AF.",
        "source": "Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS AF Guideline. Circulation. 2024;149:e1-e156",
        "evidence_level": "Level A",
        "condition": "Atrial Fibrillation"
    },
    {
        "guideline_name": "CHEST DVT Guidelines 2021",
        "section": "Diagnosis",
        "content": "For suspected DVT: Calculate Wells score. Low probability + negative D-dimer: DVT excluded. Moderate/high probability or positive D-dimer: compression ultrasound (CUS) of proximal veins. If initial CUS negative in moderate probability: repeat in 1 week or whole-leg ultrasound. Positive CUS: start anticoagulation. Consider alternative diagnoses (Baker's cyst, cellulitis, muscle strain).",
        "source": "Stevens SM, et al. CHEST Guideline on VTE Diagnosis. Chest. 2021;160:e545-e608",
        "evidence_level": "Level A",
        "condition": "Deep Vein Thrombosis"
    },
    {
        "guideline_name": "CHEST DVT Guidelines 2021",
        "section": "Treatment",
        "content": "For acute DVT: Start anticoagulation immediately. DOACs preferred (rivaroxaban, apixaban without lead-in, or LMWH lead-in then edoxaban/dabigatran). LMWH/fondaparinux for cancer-associated VTE (edoxaban/rivaroxaban also acceptable). Duration: 3 months for provoked, extended for unprovoked with low bleeding risk. Compression stockings no longer routinely recommended.",
        "source": "Stevens SM, et al. CHEST Guideline on VTE Treatment. Chest. 2021;160:e545-e608",
        "evidence_level": "Level A",
        "condition": "Deep Vein Thrombosis"
    },
    {
        "guideline_name": "ACC/AHA Hypertension Guidelines 2017",
        "section": "Diagnosis and Classification",
        "content": "Hypertension defined as BP >=130/80 mmHg (Stage 1: 130-139/80-89, Stage 2: >=140/90). Confirm with out-of-office measurements (ABPM or home BP). Screen for secondary causes in resistant HTN, early onset (<30), or atypical features. Basic evaluation: BMP, CBC, lipid panel, TSH, urinalysis, ECG. Consider echo if LVH suspected.",
        "source": "Whelton PK, et al. 2017 ACC/AHA Hypertension Guideline. Hypertension. 2018;71:e13-e115",
        "evidence_level": "Level A",
        "condition": "Hypertension"
    },
    {
        "guideline_name": "ACC/AHA Hypertension Guidelines 2017",
        "section": "Treatment",
        "content": "BP goal <130/80 for most adults with HTN. First-line agents: thiazide diuretics, ACE inhibitors, ARBs, CCBs. Start with two-drug combination if BP >=20/10 above goal. ACEi/ARB preferred in diabetes, CKD, or heart failure. Black patients: CCB or thiazide first-line. Avoid ACEi/ARB combination. Lifestyle: DASH diet, sodium <2300mg/day, exercise 90-150 min/week, weight loss.",
        "source": "Whelton PK, et al. 2017 ACC/AHA Hypertension Guideline. Hypertension. 2018;71:e13-e115",
        "evidence_level": "Level A",
        "condition": "Hypertension"
    },
    {
        "guideline_name": "ACC/AHA Hypertension Guidelines 2017",
        "section": "Hypertensive Crisis",
        "content": "Hypertensive urgency: BP >180/120 without end-organ damage - oral medications, lower BP over 24-48 hours. Hypertensive emergency: BP >180/120 WITH end-organ damage (encephalopathy, AKI, MI, aortic dissection, pulmonary edema) - IV medications in ICU, reduce MAP by 10-20% in first hour, then gradually to 160/100 over 2-6 hours. Avoid rapid drops.",
        "source": "Whelton PK, et al. 2017 ACC/AHA Hypertension Guideline. Hypertension. 2018;71:e13-e115",
        "evidence_level": "Level B",
        "condition": "Hypertension"
    },
    {
        "guideline_name": "ADA Diabetes Guidelines 2024",
        "section": "Screening and Diagnosis",
        "content": "Screen for type 2 diabetes in adults >=35, or any age with BMI >=25 and risk factors (first-degree relative with DM, high-risk ethnicity, CVD history, HTN, HDL <35 or TG >250, PCOS, physical inactivity, A1c >=5.7%). Diagnose with: FPG >=126 mg/dL, 2-hour OGTT >=200, A1c >=6.5%, or random glucose >=200 with symptoms. Confirm with repeat testing.",
        "source": "American Diabetes Association Standards of Care in Diabetes - 2024. Diabetes Care. 2024;47:S1-S321",
        "evidence_level": "Level A",
        "condition": "Diabetes"
    },
    {
        "guideline_name": "ADA Diabetes Guidelines 2024",
        "section": "Type 2 Treatment",
        "content": "A1c goal <7% for most adults (individualize). First-line: Metformin + lifestyle. If ASCVD, HF, or CKD present: Add SGLT2 inhibitor (empagliflozin, dapagliflozin) or GLP-1 RA (semaglutide, dulaglutide, liraglutide) regardless of A1c. If additional glycemic control needed: GLP-1 RA, SGLT2i, or tirzepatide preferred over SU, TZD, or basal insulin. Consider CGM for insulin users.",
        "source": "American Diabetes Association Standards of Care in Diabetes - 2024. Diabetes Care. 2024;47:S1-S321",
        "evidence_level": "Level A",
        "condition": "Diabetes"
    },
    {
        "guideline_name": "ADA Diabetes Guidelines 2024",
        "section": "Acute Complications",
        "content": "DKA criteria: glucose >250, pH <7.3, bicarbonate <18, anion gap >12, positive ketones. Treatment: IV fluids (0.9% saline initially), IV insulin infusion (0.1 units/kg/hr after fluids started), potassium replacement (add to fluids once K <5.3 and urine output confirmed). Monitor glucose hourly, BMP q2-4h. Transition to subQ insulin when anion gap closed and patient eating.",
        "source": "American Diabetes Association Standards of Care in Diabetes - 2024. Diabetes Care. 2024;47:S1-S321",
        "evidence_level": "Level A",
        "condition": "Diabetes"
    },
    {
        "guideline_name": "Berlin ARDS Definition 2012",
        "section": "Diagnosis",
        "content": "ARDS diagnosis requires: Acute onset (within 1 week of clinical insult). Bilateral opacities on chest imaging not fully explained by effusions, collapse, or nodules. Respiratory failure not fully explained by cardiac failure or fluid overload. PaO2/FiO2 ratio: Mild 200-300, Moderate 100-200, Severe <100 (on PEEP >=5 cmH2O). Risk factors include pneumonia, sepsis, aspiration, trauma, pancreatitis.",
        "source": "ARDS Definition Task Force. JAMA. 2012;307:2526-2533",
        "evidence_level": "Level A",
        "condition": "ARDS"
    },
    {
        "guideline_name": "ATS/ESICM/SCCM ARDS Guidelines 2017",
        "section": "Management",
        "content": "ARDS management: Low tidal volume ventilation (6 mL/kg predicted body weight), plateau pressure <30 cmH2O. Higher PEEP for moderate-severe ARDS. Prone positioning for >=12 hours/day if P/F <150. Neuromuscular blockade for 48 hours in early severe ARDS. Conservative fluid strategy once shock resolved. ECMO for refractory hypoxemia in experienced centers.",
        "source": "Fan E, et al. ATS/ESICM/SCCM ARDS Guidelines. Am J Respir Crit Care Med. 2017;195:1253-1263",
        "evidence_level": "Level A",
        "condition": "ARDS"
    },
    {
        "guideline_name": "Surviving Sepsis Campaign 2021",
        "section": "Definition and Diagnosis",
        "content": "Sepsis: life-threatening organ dysfunction caused by dysregulated host response to infection. Use SOFA score (>=2 point increase). qSOFA for screening: RR >=22, altered mentation, SBP <=100. Septic shock: sepsis + vasopressors needed to maintain MAP >=65 + lactate >2 mmol/L despite adequate fluid resuscitation. Hour-1 bundle: measure lactate, obtain cultures, start antibiotics, give fluids, start vasopressors if needed.",
        "source": "Evans L, et al. Surviving Sepsis Campaign 2021 Guidelines. Crit Care Med. 2021;49:e1043-e1143",
        "evidence_level": "Level A",
        "condition": "Sepsis"
    },
    {
        "guideline_name": "Surviving Sepsis Campaign 2021",
        "section": "Treatment",
        "content": "Sepsis treatment: IV crystalloid (30 mL/kg) within first 3 hours for hypotension or lactate >=4. Norepinephrine first-line vasopressor, target MAP >=65. Add vasopressin if norepinephrine dose rising. Empiric broad-spectrum antibiotics within 1 hour of recognition. De-escalate based on cultures. Source control within 6-12 hours. Hydrocortisone 200mg/day IV for refractory shock. Goal-directed fluid management after initial resuscitation.",
        "source": "Evans L, et al. Surviving Sepsis Campaign 2021 Guidelines. Crit Care Med. 2021;49:e1043-e1143",
        "evidence_level": "Level A",
        "condition": "Sepsis"
    }
]
